<DOC>
	<DOCNO>NCT00004106</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : This phase II trial study temozolomide see well work treat patient mycosis fungoides Sezary syndrome respond previous treatment .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Mycosis Fungoides Sezary Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate temozolomide patient relapsed mycosis fungoides Sezary syndrome . - Determine toxic effect drug patient . - Correlate pretreatment AGT activity tumor cell response drug patient . OUTLINE : This multicenter study . Patients receive oral temozolomide daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity maximum 1 year . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mycosis fungoides Sezary syndrome Stage IBIVB disease Must fail least one prior systemic therapy Generalized erythroderma allow Measurable disease least one indicator lesion OR evaluable disease erythrodermic patient Prior radiotherapy area measurable disease allow disease progression present site measurable disease present outside irradiation port PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR WHO 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.2 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No clinically significant peripheral venous insufficiency Other : HIV negative No poorly control diabetes mellitus No acute infection require IV antibiotic No medical condition would prevent ingestion absorption oral medication No neoplasm within past 5 year except curatively treat squamous cell basal cell skin cancer , melanoma situ , carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent growth factor epoetin alfa Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : At least 4 week since prior topical steroid Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy local control palliation recover Surgery : Recovered prior major surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>